Early Treatment of Acute Infective Tricuspid and Aortic Valve Active Endocarditis: The “Bio” Solution

Saitto G*, Mossuto E, Garatti A, Daprati A, De Vincentiis C and Menicanti L
Cardiac Surgery Unit, IRCCS Policlinico San Donato Milanese, San Donato Milanese (MI) Italy
Received: October 02, 2018; Published: October 11, 2018
*Corresponding author: Guglielmo Saitto, Cardiac Surgery Unit, IRCCS Policlinico San Donato Milanese, San Donato Milanese (MI) Italy,

Abstract

Although infective is a relatively rare infectious disease it remains a potentially lethal disease with a high morbidity and mortality rate despite medical and surgical advances. Furthermore, the best treatment and timing are often debate. We present the case of a young man with drug addiction and hepatitis B and C, who clinically presented with acute fever, dyspnea, severe anemia and hemoptysis. Acute tricuspid and aortic valve endocarditis by S. Aureus was clinically and echocardiography diagnosed and an early surgical treatment by aortic and tricuspid valve replacement by BioAorticTM and BioMitralTM prosthesis was successfully chosen.

Keywords: Infective Endocarditis; Aortic Valve Replacement; Tricuspid Valve Replacement

Introduction

Even if Infective endocarditis (IE) is relatively rare with an annual increasing incidence ranging from 10 to 15 per 100,000 person-years, it carries a high rate of morbidity and mortality [1]. Medical treatment and targeted antibiotic therapy are the first line treatment and should begin as soon as possible. Usually isolated rightside heart IE (RSE) have better outcomes compared to left (LSE) or right and left sides infection (RLSE) [2] and even if the antibiotic therapy should be completed, in some cases, like huge vegetations or persistent infection with high fever or uncontrolled systemic compromission, early surgery is recommended to prevent life-threatening complications [3]. Surgical treatment of IE has many controversies about repair or replacement the valves [4] and for RSE, also tricuspid valvectomy has been adopted in order to reduce recurrence of infection and a lower rate of postoperative complications [5].

Case Report

A 40-year old man with current drug addiction and hepatitis B and C, was admitted in to the emergency room of a peripheral hospital, presenting with acute fever, dyspnea. At hospital admission, the patient was confused, panting, feverish, tachycardic, and hypotensive. The respiratory murmur was bilateral diminished, absent in right pulmonary base due to pleural effusion. The laboratory analysis revealed leukocytosis with neutrophilia, severe anemia of unknown origin (5.5 g/dL), acute renal damage (serum creatinine 4.07 mg/dL), high PCT, metabolic acidosis with acidemia, hyperkalemia, and hyperlactatemia. The patient had multiple pulmonary condensations and right pleural effusion and was admitted to the intensive care unit for ARDS and multiple organ dysfunction treated with 12 red blood cells packages transfusion, NIV cycles and empiric antibiotic therapy (Levofloxacina, linezolid, Bactrim and Fluconazol). An episode of hemoptysis needed orotracheal intubation for 24 hours. During hospitalization, an echocardiogram was performed, which revealed a huge mobile vegetation (28x16 mm in diameter) in the tricuspid valve with a moderate regurgitation and another vegetation of 14mm on the left coronary leaflet of the aortic valve with severe eccentric jet regurgitation. Subsequently, methicillin-resistant Staphylococcus aureus (MRSA) was isolated from blood cultures.

The instituted targeted antibiotic therapy let the patient progressed favorably with significantly reduction of inflammatory markers and PCT. After two negative blood cultures the patients was transferred to internal medicine ward and the antibiotic therapy was reduced after 3 weeks by means of linezolid (1200mg /24h ev) and Daptomycin (1000mg/ die ev). After 10 days, for recurrence of fever, Piperacillin/tazobactam (4.5gr every 6 hours ev) was added. After more ten days of antibiotic therapy the patients was so transferred to our hospital for surgical treatment, in stable clinical and hemodynamic conditions, but persistent fever. Coronary angiograms reveal no coronary artery disease and the preoperative echo confirmed the huge vegetations on tricuspid (Figure 1A) and aortic valves (Figure 1B) and severe eccentric aortic regurgitation jet (Figure 1C). The Chest X Ray suggested a persistent left superior vena cava (Figure 2).
Early Treatment of Acute Infective Tricuspid and Aortic Valve Active Endocarditis: The “Bio” Solution.


Figure 1: Preoperative Echo showing the huge vegetations on tricuspid (A) and aortic (B) valves and the eccentric aortic regurgitation jet (C).

Figure 2: Preoperative chest X Ray showing a persistent left superior vena cava (PLSVC).

Figure 3: Tricuspid aortic valve (AV) and the large perforation of the left coronary cusp (LCC). RC=right coronary.

Figure 4: The huge vegetation on tricuspid valve (TV) before (A) and after (B) surgical removal.

Figure 5: Discharge Echo showing well positioning and functioning of tricuspid (A) and aortic (B) bio-prostheses.

Comment

Right-sided endocarditis represents 5-10% of total IE [6] but is more common in intravenous drug users or in presence of congenital heart defects (absence of right superior vena cava?) [7]. S. aureus is the main infective agent in community IE and carries a high rate of morbidity and mortality [8]. Isolated RSE usually has a low in-hospital mortality and a low rate of surgical treatment; on the contrary, the involvement of right and left side made the worst prognosis with a ten-year survival of 35% [2]. The high risk of these patients is not only related to the high early operative mortality but also to a significant reinfection and reintervention rate especially in case of tricuspid valve replacement [2, 9]. To reduce the artificial material, in patients without high pulmonary pressure, a conservative approach by means of tricuspid valvectomy has been proposed, with comparable long-term results [10]. Recently a large metaanalysis on 1.165 patients founded a similar long-term survival between repair and replacement the tricuspid valve with a higher risk of recurrent EI in the latter [11].

Unfortunately, in our case, a conservative surgery was not feasible for the huge vegetation of septal leaflet of TV and for a big perforation on AV leaflet. In case of replacement, a major question is still debated on the best prostheses. Our 40-year-old patient was dismissed in 7th postoperative day, afebrile, keeping only Oxacillin as antibiotic therapy. The discharge trans-thoracic echocardiogram confirmed the well positioning and functioning of both bio-prostheses in absence of paravalvular leak or significant pressure gradient (Figure 5 AB). Both native valve cultures showed no bacterial growth.
old patient was an intravenous drug user with a very high risk of reinfection. The choice of the right prosthesis is a key factor in the surgical choice and there is an active debate about the supremacy of biological over mechanical prosthesis [2,12]. The BioMitralTM and the BioAorticTM bioprosthesis have shown a good resistance to reinfection [13] so, despite the young age, in consideration of the high recurrence risk we decided to implant these all pericardial prosthesis achieving good hemodynamic and clinic results. Even if the absence of bacterial growth on the native valve is a favorable outcome predictor [14], a longer follow up could be helpful to demonstrate the validity of our choice.

References